Patent · US Active

Compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune disease

US8940722B2 · kind B2 · utility

0Cited by

0References

10Claims

0Family size

Assignee

PHENEX PHARMACEUTICALS AG · DE

Inventors

Olaf Kinzel · Heidelberg, DE
Christoph Steeneck · Dossenheim, DE
Gerald Kleymann · Bad Salzuflen, DE
Michael Albers · Rocky River, US
Thomas Hoffmann · Santa Cruz, US
Claus Kremoser · Heidelberg, DE
Sanja Perovic-Ottstadt · Ginsheim-Gustavsburg, DE
Thomas Schlüter · Heidelberg, DE

Key dates

Filing date	Feb 28, 2011
Grant date	Jan 27, 2015
Priority date	—
Expiry date	Jul 10, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D498/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides modulators for the orphan nuclear receptor RORγ and methods for treating RORγ mediated diseases by administrating these novel RORγ modulators to a human or a mammal in need thereof. Specifically, the present invention provides compounds of Formula (1) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.